source
- FDA appoints permanent heads of CDER and CBER, adding AI deputy roleThe Trump administration announced permanent appointments to two key FDA centers after a period of turnover. Michael Davis, who had been acting director of the Center for Drug Evaluation and Resea…
- Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next yearInhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…